Related Experiment Video

Updated: Jul 4, 2026

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
05:16

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

Upper gastrointestinal tumors: current status and future perspectives

Yixing Jiang1, Eric T Kimchi, Alberto J Montero

  • 1Penn State Hershey Cancer Institute, Penn State College of Medicine, 500 University Drive, Penn State Cancer Institute, Hershey, PA 17033, USA. yjiang@hmc.psu.edu

Expert Review of Anticancer Therapy
|June 7, 2008
PubMed

Insights

Despite advances in solid tumor treatments, upper gastrointestinal (GI) cancers show minimal benefit. Early detection and better understanding of GI tumor biology are crucial for improving patient survival rates.

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Solid tumor treatments have advanced due to molecular biology insights.
  • Upper gastrointestinal (GI) malignancies have not benefited significantly from these advances.
  • Patient survival for upper GI tumors remains poor due to late detection and limited treatment options.

Purpose of the Study:

  • To review current management practices for upper GI tumors.
  • To summarize recent therapeutic advances in the field.
  • To highlight challenges in treating upper GI malignancies.

Main Methods:

  • Review of current clinical practices in upper GI oncology.
  • Summary of recent therapeutic developments, including chemotherapy and biologic agents.
  • Discussion of evolving treatment paradigms, such as chemoradiation and minimally invasive procedures.

Main Results:

  • Preoperative chemoradiation is standard for esophageal cancer in the USA.
  • Adjuvant chemotherapy and chemoradiation are common for pancreatic cancer.
  • Newer agents (e.g., S-1 for gastric cancer) and minimally invasive techniques show promise.

Conclusions:

  • Upper GI malignancies require improved early detection and a deeper understanding of tumor biology.
  • Biologic agents, novel chemotherapeutics, and minimally invasive surgery offer future treatment avenues.
  • Continued research is essential to improve outcomes for patients with upper GI cancers.

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.